No Data
No Data
Recce Pharmaceuticals Secures $2 Million US Defense Funding for Topical Medication
Recce Pharmaceuticals (ASX:RCE) secured $2 million grant funding from the US Department of Defense to advance the development of the Recce 327 gel to treat burn wounds and related bacterial infections, according to a Monday filing with the Australian bourse.
Recce Pharmaceuticals Secures $2M Defense Grant
Recce Pharmaceuticals Ltd has received a $2 million grant from the U.S. Department of Defense to expedite the development of its RECCE 327 Gel for treating burn wound infections and preventing sepsis in military settings. This funding will support the evaluation of RECCE 327 Gel as an alternative to traditional antimicrobial dressings. The grant, along with a successful A$8 million institutional placement and an open share purchase plan, highlights Recce’s growing influence in the medical field and its commitment to improving health outcomes.
Recce Pharmaceuticals' Anti-Infective Drug Candidate Showed Activity Against 'Superbug' in Skin Cell Study
Recce Pharmaceuticals' (ASX:RCE) skin cell study showed the efficacy of the company's drug candidate, Recce 327, as a potential anti-infective against World Health Organization priority pathogen, acin
Recce Pharmaceuticals Fields Positive Efficacy Data From Murdoch Children's Research Institute Study
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has fielded some promising results from its latest study on the efficacy of RECCE® 327 (R327) against the multidrug-resistant (MDR), World Health Organization (WHO) priority pathogen Acinetobacter baumannii (A. baumannii).
Recce Pharmaceuticals (ASX:RCE) Firing on All Cylinders Following Completion of UTI Trial
Recce Pharmaceuticals Secures Long Cash Runway for Trials After Raising $8 Million; Plans $2 Million SPP
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has raised $8 million via an institutional placement at A$0.45 per share.
No Data